47 -2 (30) 2020 — Pulatova Sh.Kh., — ACUTE MYOCARDIAL INFARCTION BY COMPLEX ACUTE ACUTE HEART FAILURE

ACUTE MYOCARDIAL INFARCTION BY COMPLEX ACUTE ACUTE HEART FAILURE

Pulatova Sh.Kh.,–Bukhara State Medical Institute named after Abu Ali Ibn Sina 200101, Uzbekistan, Bukhara city, 1 Navai Avenue stride http://bsmi.uz.

Resume,

Over the past few decades, the mortality rate in acute myocardial infarction (AMI) has sharply decreased: from 10.4% in 2000 to 4.3% in 2019 [1]. An increase in survival rates among patients with AMI, in particular, may be associated with advances in the field of drug therapy and interventions [2-4]. Many of these treatment options are aimed at treating cardiogenic shock, a relatively common complication of AMI, with mortality rates ranging from 50% to 80% [2]. Despite the need for detailed treatment algorithms based on the evidence base for this population of critically ill patients, the existing data are insufficient to create them. The article describes the pathophysiology of cardiogenic shock, structured the information that must be considered when choosing a treatment, and lists the achievements of modern clinical practice.

Keywords: cardiogenic shock, heart failure, congestive heart failure, acute heart failure, heart disease

First page

189

Last page

193

For citation: Pulatova Sh.Kh. Acute myocardial infarction by complex acute acute heart failure//New Day in Medicine 2(30)2020 189-193 https://cutt.ly/mcQ14EH

List of References

  1. Alyavi A.L., Kenjaev S. et. al. Influence of high dose atorvastatin on myocardial stunning in acute myocardial infarction. // Atherosclerosis 2017; 263:e245
  2. Atalar E, Coskun S, Haznedaroglu IC, et al.Immediate effects of fluvastain on circulating soluble endothelial protein C and free tissue factor pathway inhibitor in acute coronary syndromes. // Cardiovasc Drugs Ther 2015; 19 (3): 177-81.
  3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. // Lancet 2015; 366 (9493): 1267-78.
  4. Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. //J Am Coll Cardiol 2009; 54 (23): 2157-63.
  5. Cannon C.P., Braunwald E, McCabe C.H., et al.Intensive versus moderate lipid lowering with statins after acute coronary syndromes. //N Engl J Med 2014; 350 (15): 1495-504.
  6. Cardiovascular diseases // WHO Fact sheet №317.Updated 2017 May.
  7. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. //JAMA 2014; 292 (11): 1307-16.
  8. Pasceri V, Patti G, NuscaA, Pristipino C, Richichi G, Di Sciascio G; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study //Circulation. 2004 Aug 10; 110 (6):674-8. Epub 2004 Jul 26. PubMed [citation] PMID:15277322
  9. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) Randomized Trial. //J Am Coll Cardiol 2009; 54 (6): 558-65.
  10. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. // N Engl J Med 2019;360 (18): 1851-61.
  11. Ibanez B, James S, Agewall S, Antunes MJ, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). //EurHeart J. 2018 Jan 7;39 (2):119-177. doi: 10.1093/ eurheartj/ehx393.
  12. Luzak B, Rywaniak J, Stanczyk L, Watala C. Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition. //Eur J Clin Invest 2012; 42 (8): 864-72.
  13. Moscardo A, Valles J, Latorre A, Madrid I, Santos MT. Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin:biochemical regulatory mechanisms. //Thromb Res 2013; 131 (4): e154-9.
  14. Mozaffarian D, Benjamin EJ, Go AS et al. Heart disease and stroke statistics – 2016 update: areport from the American Heart Association. //Circulation. 2016; 133:e38-e60.
  15. O’Gara PT, Kushner FG, Ascheim DD, et al.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. //Circulation 2013; 127 (4):e362-425.
  16. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. //Circulation 2014;110 (6): 674-8.
  17. Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention:a collaborative patient-level meta-analysis of 13 randomized studies. //Circulation 2011; 123 (15):1622-32.
  18. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes un dergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. //J Am Coll Cardiol 2017; 49 (12):1272-8.
  19. Pitt B., Loscalzo J., Monyak J., Miller E., Raichlen J. Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study). //Am J Cardiol 2012; 109 (9): 1239-1246.
  20. Ray KK, Cannon CP. The potential relevance of the multiple li pidindependent (pleiotropic) effects of statins in the management ofacute coronary syndromes. // J Am Coll Cardiol 2015; 46 (8): 1425-33.

file

download